Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial
- DOI
- 10.1038/s41467-026-72125-0
- Published
- 2026-05-14
- Container
- Nature Communications
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-026-72125-0,
title = {Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial},
author = {Ana C. Veneziani and Stephanie Lheureux and Douglas G. Millar and Neesha Dhani and Ilaria Colombo and Ainhoa Madariaga and Pamela Soberanis Pina and Swati Atale and Yin-Ling Chan and Joshua Lee and Janelle Ramsahai and Judy Quintos and Lisa Wang and Xuan Li and Valerie Bowering and Pam Ohashi and Ben Wang and Amit M. Oza},
year = {2026},
journal = {Nature Communications},
doi = {10.1038/s41467-026-72125-0},
url = {https://doi.org/10.1038/s41467-026-72125-0}
}RIS
TY - JOUR TI - Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial AU - Ana C. Veneziani AU - Stephanie Lheureux AU - Douglas G. Millar AU - Neesha Dhani AU - Ilaria Colombo AU - Ainhoa Madariaga AU - Pamela Soberanis Pina AU - Swati Atale AU - Yin-Ling Chan AU - Joshua Lee AU - Janelle Ramsahai AU - Judy Quintos AU - Lisa Wang AU - Xuan Li AU - Valerie Bowering AU - Pam Ohashi AU - Ben Wang AU - Amit M. Oza PY - 2026 JO - Nature Communications DO - 10.1038/s41467-026-72125-0 UR - https://doi.org/10.1038/s41467-026-72125-0 ER -
APA
Veneziani, A. C., Lheureux, S., Millar, D. G., Dhani, N., Colombo, I., Madariaga, A., Pina, P. S., Atale, S., Chan, Y., Lee, J., Ramsahai, J., Quintos, J., Wang, L., Li, X., Bowering, V., Ohashi, P., Wang, B., & Oza, A. M. (2026). Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial. Nature Communications. https://doi.org/10.1038/s41467-026-72125-0
Source records
- crossref · retrieved 2026-09-27T01:35:14.906Z